Improving Coronary Vascular Reserve in Coronary Microvascular Disease

First-Line Pharmacological Strategy

The American College of Cardiology recommends starting vasodilating beta-blockers, such as carvedilol 6.25 mg twice daily, uptitrated, as first-line therapy to directly increase coronary flow reserve by reducing minimal coronary resistance and increasing diastolic perfusion time 1, 2, 3
The American Heart Association and American College of Cardiology guidelines specifically recommend carvedilol 6.25 mg twice daily, uptitrated, for microvascular angina 1, 4
Ivabradine has demonstrated superiority over bisoprolol in improving coronary collateral flow and CFR in microvascular angina patients, making it a strong alternative if carvedilol is not tolerated 2, 5

The American College of Cardiology recommends adding ACE inhibitors, statins, and aspirin to all patients with documented microvascular dysfunction to directly repair endothelial function 1, 2, 3, 4, 5
ACE inhibitors improve endothelium-dependent vasodilation, particularly in patients with hypertension, diabetes, or heart failure 2, 5
Statins should be prescribed regardless of lipid levels because they improve endothelial function and reduce inflammation beyond lipid-lowering effects 2, 5
Aspirin is recommended when atherosclerosis or endothelial impairment is present 1, 4

The American College of Cardiology recommends implementing smoking cessation and weight loss immediately because cardiovascular risk factors significantly impair microvascular function and directly reduce coronary vascular reserve 1, 2
Weight loss and cardiovascular risk factor modification are essential components that improve endothelial function and microvascular remodeling 2

The American College of Cardiology recommends adding ranolazine or substituting non-dihydropyridine calcium channel blockers if beta-blockers are ineffective or not tolerated 1, 2, 3
Ranolazine reduces mechanical compression of the coronary microcirculation and improves coronary self-regulation, with evidence showing benefit primarily in patients with impaired CFR 2, 5
Non-dihydropyridine calcium channel blockers can be substituted when beta-blockers fail, as they slow heart rate and increase diastolic perfusion time 2, 3

The American College of Cardiology recommends confirming the diagnosis with invasive coronary function testing (CFR and IMR measurement) before initiating microvascular-directed therapy because tailored treatment based on invasive testing significantly reduces anginal symptoms compared to non-guided therapy 2, 3, 5
The CorMicA trial demonstrated that stratified medical therapy guided by invasive coronary physiology testing improved angina severity by 11.7 units on the Seattle Angina Questionnaire 6
CFR <2.0 by thermodilution reflects the inability to increase coronary flow above 2 times resting flow—this is the specific parameter defining impaired coronary vascular reserve 1, 4
IMR ≥25 indicates microvascular dysfunction and helps distinguish structural from functional causes 1, 6, 7

The American College of Cardiology recommends never using beta-blockers if vasospastic angina is present because they can precipitate spasm by leaving alpha-mediated vasoconstriction unopposed by beta-mediated vasodilation 2, 5
Avoid vasodilators in hyperthyroidism-related angina due to risk of reflex tachycardia 2
Nitrate tolerance develops with continuous administration, requiring intermittent dosing schedules if long-acting nitrates are used 2
Recognize that 20-30% of patients remain symptomatic despite traditional antianginal therapy, necessitating consideration of tricyclic antidepressants for enhanced pain perception 2, 5

The European Heart Journal recommends reassessing CFR after 3-6 months of therapy using either invasive coronary function testing or non-invasive imaging to objectively measure improvement in coronary vascular reserve 7
Continuous thermodilution-derived measurements show higher reproducibility than bolus thermodilution for CFR assessment 7